focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I was unable to top up at 120p all the days of April since the 4th placing .
Sold the holding with main broker for 240p yesterday and taking a loss on that 2021 buy.
Spread 8.3%.
Much the same price today.
Bad luck in hindsight the failed top ups after the placing last month.
Placing 4/4/24 150eu 1.29p eq... brokers chart shows 117p on 18/4/2024.
25/8/21 485p High
25/2/21 Buy 330p
Just voted too
C'mon Faron - we'll all been so patient, so please pull this off and get snapped up!
Voted and will again tomorrow!
Voted
Plus you can vote again tomorrow!
Can't wait for Mondays results !!!!
Been away for a bit but a fantastic recovery over the past week.
Agreed you don't nominate a failure..as juho said 2024 is the year it happens.
Are you in or out ?
Like Itsall says - you don't stick an invention like this up for such a prestigious award if there's a chance it will fall flat in failure . Its almost like a stamp of approval from this organisation , and highlighting just what a game changer Bex is about to become . I think the confidence that was lost in the market with those financing jitters has pretty much gone now it seems - so it's as if we are starting back from where we were a month or so ago - but with a new CEO , and much more tangible targets and objectives this year . Whether or not they win this category , it's a fitting tribute to the pair , who rightly deserve it .
Voted!
Neat little video to accompany the nomination .
https://www.youtube.com/watch?v=dHYW3lOKWpQ&t=65s
Well done.
We can all vote for them too -
https://www.epo.org/en/news-events/european-inventor-award/meet-the-finalists/sirpa-jalkanen-and-markku-jalkanen
A new treatment that recruits the body’s immune system to fight cancer more effectively was developed by Sirpa and Markku Jalkanen. Their treatment offers new hope to patients resistant to other therapies.
Killing almost 2 million people annually, cancer is Europe’s second most common cause of death. Myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) are two types of blood cancer with typically bleak outcomes and few modern treatment options. However, clinical trials of the Jalkanens' invention, Bexmarilimab (also known as Clevegen), have produced remarkable results, demonstrating a 50% remission rate in patients with AML and MDS resistant to other therapies. New data reveals a high response rate of 87.5% and a long-lasting reduction of cancer cells in patients for whom chemotherapy had already failed.
Bexmarilimab works by blocking CLEVER-1, a protein found in certain white blood cells. With CLEVER-1 receptors switched off, immune-suppressing cells transform into immune-activators, recruiting other cells for a joint attack on tumours and malignancies. Bexmarilimab's unique approach sets it apart from other therapies, but by boosting the body's natural defences, it can also enhance the effectiveness of therapies commonly used to treat solid tumours and blood malignancies, opening up the benefits of immunotherapy to more patients.
It's like they know Bex works!
This could help raise our profile -
https://www.epo.org/en/news-events/european-inventor-award/meet-the-finalists/sirpa-jalkanen-and-markku-jalkanen
It would be nice to see the Faron story hit the UK news outlets sometime soon.
There's been a fair amount of dilution since Markku's comment but I wouldn't have thought $1-2bn was out of the question given what we have for MDS. But the real prize is Bexcombo, where I would guess that similar Ph2 data would put us into the $5-10bn range which happens to be the sort of deal Bayer are looking for and maybe one reason Christine Roth is on the Board.
So I personally doubt there will be an acquisition this year. I still believe the order of events to be:
1. Early Phase 2 results next week
2. Fund raise / loan of Euro 10-27m in June (at least 10m is required to maintain covenants and avoid another hiccup)
3. FDA feedback on path to approval for MDS this summer
4. Partner deal for MDS late this year or early next year
5. Funds from partner deal provide cash for Bexcombo Phase 1 and Phase 2, starting early 2025
6. Acquisition by Big Pharma (2026?)
Last year when we were about £2.50 Marku said you can add a zero when partner joins the journey.
During may Q&A's over the years , the consensus seemed to be that a company with a pioneering immunotherapy drug like Bex , that could be proven effective , commercialised and had multiple other combination opportunities in oncology would be worth $1-2 billion . The cancer Immunotherapy market is growing massively . I think Markku's last presentation in the UK he spoke of $50 billion market Bex could be applied to . The whole cancer Immunotherapy market is nearer$125 billion and expected to grow 18% a year . A partnership deal won't realise that value straight away , but if it puts Faron into the category of profit making and generating cash for future growth , then why not a £10 SPin the near future ?. Thats only a $700m Mcap . This partner deal may be only one of many to come , if it isn't a big exclusive tie up . So maybe one step at a time . ( Disclaimer - we've all been here long enough to know that until we get the big RNS - anything might nothing may happen lol )
Can buy through Barclays.
Hi Sax ,hopefully us LTHs faith in Faron will be rewarded soon. I wonder where the sp would rerate to if we get a partner on board, given the low freefloat of shares.
Does It appear that with Juho's enthusiasm In the Interview coupled with the trading on Nas that a Partner Is already on board. He seemed very relaxed. IMO
Yes , been good steady demand on Nas , couple of massive days , now running at about 200k a day . Setting up nicely for next week .
We are catching up.
Can't but with aj Bell
Most of the action is on the Nasdaq. It's had some strong trading over the last few days.
Spread showing 4.29% here today , much better then yesterdays 10%
Would of been good idea to buy into recovery here.
Google has 117p 17/4/24 less then a month ago now 238p ...100% increase.
They are still down 22% on the one year and down 217% over 5 years.
My broker again shows 0% gain , this site up another 8% and google has up 10%.
Must add to volatility of small caps when some brokers feeds not correct, more so affecting the spread bet type of short time traders.
He is pretty confident 2024 is gonna be big for Faron
https://youtu.be/d3IrzHHS6mw?si=ghjy3JeKG454vGQ2